Updates are available Correction dated 2022-01-18
Click to view Correction: https://doi.org/10.1038/s41585-022-00569-2
-
Authors
Bandini, Marco
Ahmed, Mohamed
Basile, Giuseppe
Watkin, Nicholas
Master, Viraj
Zhu, Yao
Prakash, Gagan
Rodriguez, Alejandro https://orcid.org/0000-0001-8954-153X
Ssebakumba, Mbaaga K. https://orcid.org/0000-0002-4654-923X
Leni, Riccardo
Cirulli, Giuseppe Ottone
Ayres, Ben
Compitello, Rachel
Pederzoli, Filippo https://orcid.org/0000-0003-3873-7465
Joshi, Pankaj M.
Kulkarni, Sanjay B.
Montorsi, Francesco
Sonpavde, Guru https://orcid.org/0000-0002-1010-9611
Necchi, Andrea https://orcid.org/0000-0002-3007-2756
Spiess, Philippe E. https://orcid.org/0000-0002-5723-1972
- License Information
-
More Information
Article History
Accepted: 8 December 2021
First Online: 22 December 2021
Change Date: 18 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41585-022-00569-2
Competing interests
: G.S. declares advisory board input for BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, AstraZeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Immunomedics/Gilead, Scholar Rock, and G1 Therapeutics; research support from Sanofi, AstraZeneca, Immunomedics/Gilead, QED, Predicine, and BMS; travel support from BMS and AstraZeneca; honoraria from the Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Uptodate, as an Editor of Elsevier Practice Update Bladder Cancer Center of Excellence; positions on trial steering committees for BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and for AstraZeneca, EMD Serono, Debiopharm (paid), The other authors declare no competing interests.
